BioSpace News Archive

InMed Pharmaceuticals Inc. (Nasdaq: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the clinical development of cannabinol today announced that it has closed the previously

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the completion of the rolling submission for the supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking marketing approval for Xywav™

Athersys, Inc., a regenerative medicine company developing MultiStem® cell therapy, announced that it has entered into a cooperation agreement with HEALIOS K.K., the Company’s largest shareholder and one of its commercial partners, and Dr. Hardy TS Kagimoto, a member of the Company’s Board and the Chairman and Chief Executive Officer of Healios.

Eyenovia, Inc ., (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that it will host a Key Opinion Leader (KOL) webinar, entitled: “Presbyopia in Focus: Unlocking one of the Biggest Market Opportunities in Ophthalmology,” on Monday, February 22, 2021 at 1:00pm Eastern Time.

The Cystic Fibrosis Foundation announced that it has awarded up to $2.17 million to Beyond Air® to support the development of a portable inhaled nitric oxide treatment for nontuberculous mycobacteria, difficult-to-treat bacteria that infect the lungs of people with cystic fibrosis.

InVivo Therapeutics Announces Publication in Peer-Reviewed Journal of Neurosurgery: Spine Manuscript Details Complete Six-Month INSPIRE 1.0 Primary Endpoint Study Results

Mainstay Medical Holdings plc announced the closing of an equity financing in which it raised gross proceeds of US$108 million.

Helix BioPharma Corp. (TSX:HBP) , a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced the appointment of Dr. Frank Gary Renshaw to the Companys Scientific Advisory Board.

Orsini Specialty Pharmacy, a leader in rare diseases and gene therapies, announced that it has been selected by Regeneron Pharmaceuticals, Inc. as the exclusive specialty pharmacy partner for EvkeezaTM.

Perrigo Company plc (NYSE; TASE: PRGO) today announced that it will release its fourth quarter and calendar year 2020 financial results on Monday, March 1, 2021 . The Company will also host a conference call beginning at 8:00 a.m. (EST) .